Autolus Therapeutics (AUTL) was upgraded by Truist Financial Corporation to "strong-buy".
Autolus Therapeutics (AUTL) was upgraded by Zacks Research from "strong sell" to "hold".
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 [Yahoo! Finance]
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight